WO2007109183A3 - Mutations et polymorphismes de la tyrosine kinase 1 liée au fms - Google Patents

Mutations et polymorphismes de la tyrosine kinase 1 liée au fms Download PDF

Info

Publication number
WO2007109183A3
WO2007109183A3 PCT/US2007/006723 US2007006723W WO2007109183A3 WO 2007109183 A3 WO2007109183 A3 WO 2007109183A3 US 2007006723 W US2007006723 W US 2007006723W WO 2007109183 A3 WO2007109183 A3 WO 2007109183A3
Authority
WO
WIPO (PCT)
Prior art keywords
fltl
mutations
polymorphisms
mutant
various aspects
Prior art date
Application number
PCT/US2007/006723
Other languages
English (en)
Other versions
WO2007109183A2 (fr
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007109183A2 publication Critical patent/WO2007109183A2/fr
Publication of WO2007109183A3 publication Critical patent/WO2007109183A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne de manière générale le test analytique d'échantillons tissulaires in vitro et plus particulièrement des aspects des polymorphismes et mutations génétiques du gène FLT1. Elle concerne de nouvelles mutations et de nouveaux polymorphismes nucléotidiques simples (SNP) du FLT1 qui sont utiles dans le diagnostic et le traitement de sujets qui en ont besoin. En conséquence, les divers aspects de la présente invention concernent des polynucléotides codant pour des mutations du FLT1 selon l'invention, des vecteurs d'expression codant pour les polypeptides FLT1 mutants de l'invention et des organismes qui expriment le FLT1 mutant et les polynucléotides polymorphes et/ou les polypeptides FLT1 mutants/polymorphes de l'invention. Les divers aspects de la présente invention concernent en outre des méthodes et des kits de diagnostic/théranostic utilisant les mutations et polymorphismes du FLT1 selon l'invention pour identifier des individus prédisposés à une maladie ou pour classifier des individus en fonction de leur réponse à un médicament, des effets secondaires ou de la dose de médicament optimale.
PCT/US2007/006723 2006-03-20 2007-03-16 Mutations et polymorphismes de la tyrosine kinase 1 liée au fms WO2007109183A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78413206P 2006-03-20 2006-03-20
US60/784,132 2006-03-20

Publications (2)

Publication Number Publication Date
WO2007109183A2 WO2007109183A2 (fr) 2007-09-27
WO2007109183A3 true WO2007109183A3 (fr) 2008-09-18

Family

ID=38523006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006723 WO2007109183A2 (fr) 2006-03-20 2007-03-16 Mutations et polymorphismes de la tyrosine kinase 1 liée au fms

Country Status (1)

Country Link
WO (1) WO2007109183A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2894231B1 (fr) * 2009-08-04 2017-01-04 F. Hoffmann-La Roche AG Sensibilité aux inhibiteurs de l'angiogenèse
WO2018090257A1 (fr) * 2016-11-16 2018-05-24 深圳华大基因研究院 Polypeptide et son application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1130123A2 (fr) * 2000-02-24 2001-09-05 AstraZeneca AB Méthode diagnostique
EP1338655A1 (fr) * 2000-10-03 2003-08-27 Kyowa Hakko Kogyo Co., Ltd Substance inhibant la fixation de la molecule de transduction de signal au recepteur kdr/flk-1 phosphoryle au niveau de la tyrosine a la position 1175 et technique d'utilisation
WO2005070431A1 (fr) * 2004-01-22 2005-08-04 Novartis Ag Derives de pyrazolo[1,5-a]pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase
EP1655368A1 (fr) * 1999-04-16 2006-05-10 Genentech, Inc. Variantes du facteur de croissance cellulaire endothélial et leur usages

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655368A1 (fr) * 1999-04-16 2006-05-10 Genentech, Inc. Variantes du facteur de croissance cellulaire endothélial et leur usages
EP1130123A2 (fr) * 2000-02-24 2001-09-05 AstraZeneca AB Méthode diagnostique
US20040091912A1 (en) * 2000-02-24 2004-05-13 Astrazeneca Ab, A Swedish Corporation Diagnostic method
EP1338655A1 (fr) * 2000-10-03 2003-08-27 Kyowa Hakko Kogyo Co., Ltd Substance inhibant la fixation de la molecule de transduction de signal au recepteur kdr/flk-1 phosphoryle au niveau de la tyrosine a la position 1175 et technique d'utilisation
WO2005070431A1 (fr) * 2004-01-22 2005-08-04 Novartis Ag Derives de pyrazolo[1,5-a]pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREKKEN R ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR TARGETING OF SOLID TUMORS", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS, vol. 21, no. 6B, 1 November 2001 (2001-11-01), pages 4221 - 4230, XP009033823, ISSN: 0250-7005 *
FONG T A T ET AL: "SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 59, no. 1, 1 January 1999 (1999-01-01), pages 99 - 106, XP002378513, ISSN: 0008-5472 *
MENENDEZ DANIEL ET AL: "A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, no. 5, January 2006 (2006-01-01), pages 1406 - 1411, XP002483893, ISSN: 0027-8424 *
ROCKWELL P ET AL: "IN VITRO NEUTRALIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVATION OF FLK-1 BY A MONOCLONAL ANTIBODY", MOLECULAR AND CELLULAR DIFFERENTIATION, CRC PRESS, BOCA RATON, US, vol. 3, no. 1, 1 January 1995 (1995-01-01), pages 91 - 109, XP009065009, ISSN: 1065-3074 *

Also Published As

Publication number Publication date
WO2007109183A2 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2007016532A3 (fr) Mutations et polymorphismes de hdac4
WO2006130527A3 (fr) Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes
Kunugi et al. No association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder in a Japanese population: a multicenter study
Breitenstein et al. Are there meaningful biomarkers of treatment response for depression?
EP2363505A3 (fr) Diagnostic du mélanome par l'analyse des acides nucléiques
BRPI0520530A2 (pt) método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb
WO2009009752A3 (fr) Modèles génétiques pour le classement des risques de cancer
EP2293074A3 (fr) Procédé pour le diagnostic de maladies neuro-dégénératives
WO2009140550A3 (fr) Diagnostic de mélanome et de lentigo solaire par analyse d'acides nucléiques
NZ600235A (en) Methods and compositions for the assessment of drug response
WO2006110478A3 (fr) Mutations et polymorphismes du recepteur du facteur de croissance epidermique
WO2006073682A3 (fr) Test diagnostique
WO2008021115A3 (fr) Tests de diagnostic utilisant des rapports d'expression génique
WO2007016367A3 (fr) Procedes, kits, systemes et bases de donnees relatifs a des maladies neoplasiques
EP2287340A3 (fr) Procédé de diagnostic et traitement d'une maladie mentale
WO2007022041A3 (fr) Mutations et polymorphismes de l'hdac3
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2005118403A3 (fr) Procedes pour detecter l'expression genique dans des cellules du sang peripherique et utilisations de ces procedes
WO2007146668A3 (fr) Utilisation d'imp3 en tant que marqueur pronostique de cancer
WO2007030455A3 (fr) Mutations et polymorphismes de hdac10
WO2007038073A3 (fr) Mutations et polymorphismes de l’hdac11
WO2007030454A3 (fr) Mutations et polymorphismes de hdac9
WO2007109183A3 (fr) Mutations et polymorphismes de la tyrosine kinase 1 liée au fms
WO2007058992A3 (fr) Mutations et polymorphismes de hdac6
WO2009133197A3 (fr) Niveaux d’april dans le sérum et utilisation dans des procédés de diagnostic

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753356

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07753356

Country of ref document: EP

Kind code of ref document: A2